Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: A role for organ damage markers

Journal of Hypertension

Volumn 30, Issue 6, 2012, Pages 1056-1064

  Volpe, Massimo ^a,b   Battistoni, Allegra ^b   Tocci, Giuliano ^b   Rosei, Enrico Agabiti ^c   Catapano, Alberico L ^d   Coppo, Rosanna ^e   Del Prato, Stefano ^f   Gentile, Sandro ^g   Mannarino, Elmo ^h   Novo, Salvatore ⁱ   Prisco, Domenico ^j   Mancia, Giuseppe ^k  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b IRCCS NEUROMED   (Italy)

^c UNIVERSITY OF BRESCIA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

^f UNIVERSITY OF PISA   (Italy)

^g SECOND UNIVERSITY OF NAPLES   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ UNIVERSITY OF PALERMO   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k SAN GERARDO HOSPITAL   (Italy)

more..

Author keywords

cardiovascular risk; estimated glomerular filtration rate; left ventricular hypertrophy; metabolic syndrome; microalbuminuria; prevention; SCORE; target organ damage

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ALBUMINURIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL EVALUATION; CORONARY RISK; ELECTROCARDIOGRAPHY; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INTERVENTION STUDY; MEDLINE; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MICROALBUMINURIA; OBSERVATIONAL METHOD; ORGAN INJURY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

EID: 84861056940     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3283525715     Document Type: Review

References (90)

1. Rodríguez-Artalejo F, Guallar E, Borghi C, Dallongeville J, De Backer G, Halcox JP, Hernandez-Vecino R, et al. Rationale and methods of the European Study on Cardiovascular Risk Prevention and Management in Daily Practice (EURIKA). BMC Public Health 2010; 10:382-390.
2. Perego F, Renesto E, Arquati M, Scandiani L, Cogliati C, Torzillo D, et al. Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: CArdiovascular PREvention Sacco Study (CAPRESS). Intern Emerg Med 2010. [Epub ahead of print]
3. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, et al., ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007; 25:1751-1762.
4. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JPA, et al. The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate healthcare interventions: explanation and elaboration. PLoS Med 2009; 6:e1000100.
5. Conroy RM, Pyörälä K, Fitzgerald AP, Sans S, Menotti A, De Backer G, Ducimetiére P, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24:987-1003.
6. Koren MJ, Deveraux R, Casale PN, Savaga DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345-352.
7. Kannel WB, Schatzkin A. Sudden death: lessons from subsets in population studies. J Am Coll Cardiol 1985; 5 (Suppl 6):141B-149B.
8. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786-1793.
9. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Porcellati C. Prognostic value of new electrocardiographic method for diagnosis of left ventricular hypertrophy in essential hypertension. J Am Coll Cardiol 1998; 31:383-390.
10. Sundstrom J, Lind L, Arnlov J, Zethelius B, Andren B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in population of elderly men. Circulation 2001; 103:2346-2351.
11. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F. Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35:580-586.
12. Verdecchia P, Carini G, Circo A, Novellini E, Giovannini E, Lombardo M, Solinas P, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: theMAVI study. JAmColl Cardiol 2001; 38:1829-1835.
13. Machado D, Crow RS, Boland LL, Hannan PJ, Taylor HA Jr., Folsom AR. Electrocardiographic findings and incident coronary heart disease among participants in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Cardiol 2006; 97:1176-1181.
14. De Bacquer D, De Backer G, Kornitzer M, Blackburn H. Prognostic value of ECG for total, cardiovascular disease, and coronary heart disease death in men and woman. Heart 1998; 80:570-577.
15. Levi D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. N Engl J Med 1990; 322:1561-1566.
16. Dunn F, McLenechan J, Isles CG, Brown I, Dargie HJ, Lever AF, Lorimer AR, et al. Left ventricular hypertrophy and mortality in hypertension: an analysis of data from Glasgow Blood Pressure Clinic. J Hypertens 1990; 8:775-782.
17. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, Foster E, et al. 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Writing Committee Members. Circulation 2010; 122:e584-e636.
18. Wacthell K, Okin PM, Olsen MH, Dahlof B, Deveraux RB, Ibsen H, Kjeldsen SE, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the Life study. Circulation 2007; 116:700-705.
19. Mathew J, Sleigh P, Lonn E, Jhonstone D, Pogue J, Yi Q, Bosch J, et al. Heart Outcome Prevention Evaluation (HOPE) Investigators. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by angiotensin-convertingenzyme inhibitor Ramipril. Circulation 2001; 104:1615-1621.
20. Okin P, Deveraux R, Jern S, Kjeldsen SE, Julius S, Niemine MS, Snapinn S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343-2349.
21. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti- Rosei E. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13:1091-1095.
22. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Gattobigio R, Zampi I, Rebordi G, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97:48-54.
23. Devereux RB, Wachtell K, Gerdts E, Boman K, Nieminen MS, Papademetriou V, Rokkedal J, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292:2350-2356.
24. Pierdomenico SD, Cuccurullo F. Risk reduction after regression of echocardiographic left ventricular hypertrophy in hypertension: a meta-analysis. Am J Hypertens 2010; 23:876-881.
25. Cuspidi C, Meani S, Valerio C, Fusi V, Sala C, Zanchetti A. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 2006; 24:1671-1677.
26. Brugts JJ, Knetsch AM, Mattace-Raso FU, Hofman A, Witteman JC. Renal function and risk of myocardial infarction in an elderly population: the Rotterdam Study. Ann Intern Med 2005; 165:2659-2665.
27. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension 2003; 42:1050-1065.
28. Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Coresh J, et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003; 63:1121-1229.
29. Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The Hypertension Detection and Follow-up Program Cooperative Group. Hypertension 1989; 13 (5 Suppl):180-193.
30. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillal A, Jardine M, Patel A, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009; 20:1813-1821.
31. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134:629-636.
32. Rahman M, Pressel S, Davis BR, Nwachuku C, Wright JT Jr., Whelton PK, Barzilay J, et al. Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 2006; 144:172-180.
33. Shara NM, Resnick HE, Lu L, Xu J, Vupputuri S, Howard BV, et al. Decreased GFR estimated by MDRD or Cockcroft-Gault equation predicts incident CVD: the strong heart study. J Nephrol 2009; 22:373-380.
34. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12:218-225.
35. Segura J, Campo C, Gil P, Roldan C, Vigil L, Rodicio JL, Ruilope LM. Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15:1616-1622.
36. Viazzi F, Leoncini G, Conti N, Tomolillo C, Glachero G, Vercelli M, Deferrari G, et al. Combined effect of albuminuria and estimated glomerular filtration rate on cardiovascular events and all-cause mortality in uncomplicated hypertensive patients. J Hypertens 2010; 28:848-855.
37. Weiner DE, Tabatabai S, Tighiouart H, Elsayed E, Bansal N, Griffith J, et al. Cardiovascular outcomes and all-cause mortality: exploring the interaction between CKD and cardiovascular disease. Am J Kidney Dis 2006; 48:392-401.
38. Di Angelantonio E, Danesh J, Eiriksdottir G, Gudnason V. Renal function and risk of coronary heart disease in general population: new prospective study and systematic review. PLoS Med 2007; 4:1497-1506.
39. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010; 375:2073-2081.
40. Go AS, Glenn M, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Eng J Med 2004; 351:1296-1305.
41. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, Kanashiki M, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006; 69:1264-1271.
42. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002; 13:745-753.
43. Meisinger C, Döring A, Löwel H, KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J 2006; 27:1245-1250.
44. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, Salem DN, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of communitybased studies. J Am Soc Nephrol 2004; 15:1307-1315.
45. Ryan TP, Fisher SG, Elder JL, Winters PC, Beckett W, Tacci J, Sloand JA. Increased cardiovascular risk associated with reduced kidney function. Am J Nephrol 2009; 29:620-625.
46. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the US population. Am J Epidemiol 2008; 167:1226-1234.
47. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: the Hoorn Study. Kidney Int 2002; 62:1402-1407.
48. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41:47-55.
49. Van Biesen W, De Bacquer D, Verbeke F, Delanghe J, Lameire N, Vanholder R. The glomerular filtration rate in an apparently healthy population and its relation with cardiovascular mortality during 10 years. Eur Heart J 2007; 28:478-483.
50. Sciarretta S, Valenti V, Tocci G, Pontremoli R, Rosei EA, Ambrosioni E, Costa V, et al. Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - developing education and awareness on microalbuminuria in patients with hypertensive disease study. J Hypertens 2010; 28:251-258.
51. Matsushita K, Selvin E, Bash LD, Astor BC, Coresh J. Risk implications of the new CKD epidemiology collaboration (CKD-EPI) equation compared with the MDRD study equation for estimated GFR: the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis 2010; 55:648-659.
52. Yuyun M, Adler A, Wareham N. What is the evidence that microalbuminuria is a predictor of cardiovascular disease eventš Curr Opin Nephrol Hypertens 2005; 14:271-276.
53. Nerpin E, Ingelsson E, Riserus U, Sundstrom J, Larsson A, Jobs E, et al. The combined contribution of albuminuria and glomerular filtration rate to the prediction of cardiovascular mortality in elderly men. Nephrol Dial Transplant 2011; 26:2820-2827.
54. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 2000; 35:898-903.
55. Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, et al. Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 1999; 19:617-624.
56. Deckert T, Yokoyama H, Mathiesen E, Ronn B, Jensen T, Feldt- Rasmussen B, Borch-Johnsen K, et al. Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes. BMJ 1996; 312:871-874.
57. Rossing P, Hougaard P, Borch-Johnsen K, Parving HH. Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study. BMJ 1996; 313:779-784.
58. Gimeno Orna JA, Boned Juliani B, Lou Arnal LM, Castro Alonso FJ. Microalbuminuria and clinical proteinuria as the main predictive factors of cardiovascular morbidity and mortality in patients with type 2 diabetes. Rev Clin Esp 2003; 203:526-531.
59. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, et al. HOPE Study Investigators. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286:421-426.
60. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, et al. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. PREVEND Study Group. J Intern Med 2001; 249:519-526.
61. Klausen KP, Parving HH, Scharling H, Jensen JS. The association between metabolic syndrome, microalbuminuria and impaired renal function in the general population: impact on cardiovascular disease and mortality. J Intern Med 2007; 262:470-478.
62. Foster MC, Hwang SJ, Larson MG, Parikh NI, Meigs JB, Vasan RS, Wang TJ, et al. Cross-classification of microalbuminuria and reduced glomerular filtration rate: associations between cardiovascular disease risk factors and clinical outcomes. Arch Intern Med 2007; 167:1386-1392.
63. Yuyun MF, Khaw KT, Luben R, Welch A, Bingham S, Day NE, Wareham NJ. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population: the EPIC-Norfolk study. Am J Epidemiol 2004; 159:284-293.
64. Perkovic V, Verdon C, Ninomiya T, Barzi F, Cass A, Patel A, Jardine M, et al. The relationship between proteinuria and coronary risk: a systematic review and meta-analysis. PLoS Med 2008; 5:1486-1495.
65. Wachtell K, Ibsen H, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, Dahlof B, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE Study. Ann Intern Med 2003; 139:901-906.
66. Klausen K, Borch-Johnsen K, Feldt-Rasmussen B, Jensen J, Clausen P, Scharling H, Appleyard M, et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 2004; 110:32-35.
67. Hillege H, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population for the Prevention of Renal and Vascular End Stage Disease (PREVEND) study group. Circulation 2002; 106:1777-1782.
68. Arnlöv J, Evans JC, Meigs JB, Wang TJ, Fox CS, Levy D, Benjamin EJ, et al. Low-grade albuminuria and incidence of cardiovascular disease events in nonhypertensive and nondiabetic individuals: the Framingham Heart Study. Circulation 2005; 112:969-975.
69. Rydén L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, Cosentino F, Jonsson B, et al. Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD). Guidelines on diabetes, prediabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study ofDiabetes (EASD). EurHeart J 2007; 28:88-136.
70. Qiao Q, Laatikainen T, Zethelius B, Stegmayr B, Eliasson M, Jousilahti P, Tuomilehto J. Comparison of definitions of metabolic syndrome in relation to the risk of developing stroke and coronary heart disease in Finnish and Swedish cohorts. Stroke 2009; 40:337-343.
71. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24:683-689.
72. Lakka HM, Laaksonen D, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288:2709-2716.
73. Nilsson PM, Engström G, Hedblad B. The metabolic syndrome and incidence of cardiovascular disease in nondiabetic subjects: a population- based study comparing three different definitions. Diabet Med 2007; 24:464-472.
74. Mancia G, Bombelli M, Corrao G, Facchetti R, Madotto F, Giannattasio C, Trevano FQ, et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007; 49:40-47.
75. Sundström J, Risérus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332:878-882.
76. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italienne GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110:1245-1250.
77. Schillaci G, Pirro M, Vaudo G, Gemelli F, Marchesi S, Porcellati C, Mannarino E. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004; 43:1817-1822.
78. Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Stanley A, Forrest E, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003; 108:414-419.
79. Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173:309-314.
80. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56:1113-1132.
81. Simons L, Simons J, Friedlander Y, McCallum J. Does a diagnosis of the metabolic syndrome provide additional prediction of cardiovascular disease and total mortality in the elderly? The Dubbo Study. Med J Aust 2007; 186:400-403.
82. Mente A, Yusuf S, Islam S, McQueen MJ, Tanomsup S, Onen CL, Rangarajan S, et al. Metabolic syndrome and acute myocardial infarction. J Am Coll Cardiol 2010; 55:2390-2398.
83. Neil Thomas GN, Phillips AC, Carroll D, Gale CR, Batty GD. The metabolic syndrome adds utility to the prediction of mortality over its components: the Vietnam experience study. Atherosclerosis 2010; 210:256-261.
84. DECODE Study Group. Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. Eur J Cardiovasc Prev Rehabil 2007; 14:192-199.
85. Sehestedt T, Jeppesen J, Hansen TW, Wachtell K, Ibsen H, Torp- Pedersen C, Hildebrandt P, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010; 31:883-891.
86. Leoncini G, Ratto E, Viazzi F, Conti N, Falqui V, Parodi A, Tomolillo C, et al. Global risk stratification in primary hypertension: the role of the kidney. J Hypertens 2008; 26:427-432.
87. Viazzi F, Parodi D, Leoncini G, Vettoretti S, Ratto E, Vaccaio V, Ravera M, et al. Optimizing global risk evaluation in primary hypertension: the role of microalbuminuria and cardiovascular ultrasonography. J Hypertens 2004; 22:907-913.
88. Nambi V, Chambless L, FolsomAR, He M,Hu Y,Mosley T, Volcik K, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol 2010; 55:1600-1616.
89. Novo S, Caritá P, Corrado E, Muratori I, Pernice C, Tantillo R, Novo G. Preclinical carotid atherosclerosis enhances the global cardiovascular risk and increases the rate of cerebro and cardiovascular events in a five-year follow-up. Atherosclerosis 2010; 211:287-290.
90. Novo S, Visconti CL, Amoroso GR, Corrado E, Novo G. Asymptomatic carotid lesions add to cardiovascular risk prediction. Eur J Cardiovasc Prev Rehabil 2010; 17:514-518.